Overview

Switch Maintenance Pembrolizumab in Patients With NSCLC After First Line Platinum Doublet Chemotherapy

Status:
Active, not recruiting

Trial end date:
2021-07-31

Target enrollment:

Participant gender:

Summary

Single arm one stage Phase II study: post 4-6 cycles platinum doublet chemotherapy for patients with metastatic Non Small Cell Lung Cancer (NSCLC) offering Pembrolizumab as maintenance therapy to non-progressors with primary endpoint: Immune Related Progression Free Survival (irPFS) at 1 year. Aim to show that this is at least 25% (compared to an expected 12% 1 year PFS based on the Pemetrexed and Erlotinib maintenance trials).

Phase:

Phase 2

Details

Lead Sponsor:

Bank of Cyprus Oncology Centre

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Pembrolizumab